Prior authorization / Coding and denial risk

CPT and HCPCS codes for photodynamic therapy (PDT) and related products are payable only when the selection and medical‑necessity criteria in this policy are met. Codes for interventions listed as experimental/investigational in this policy may be denied.

• Covered HCPCS: J7308 (ALA 20%), J7345 (ALA 10% gel) — only if policy criteria met.
• Disallowed/Investigational techniques (no specific CPT/HCPCS codes): thermal PDT, repetitive daylight PDT, intense pulsed light, microwave therapy, microneedling, non-ablative fractional thulium laser.

Prior authorization — administrative note

This excerpt does not specify a formal payer prior authorization requirement for PDT or other AK treatments. Where prior authorization processes exist at the plan level, providers must follow the payer’s routine prior authorization workflows.

• No explicit prior authorization rules listed in this policy excerpt.
• Verify member benefits and any plan-level prior authorization requirements before treatment.

Prior authorization — evidence‑informed guidance

Evidence-informed guidance in the clinical background supports using PDT (ALA or MAL) as an option for patients with extensive or refractory AKs and for certain high‑risk populations (e.g., organ transplant recipients). The policy does not establish step‑therapy requirements but summarizes evidence that may inform clinical decision-making.

• Guideline-style recommendations: PDT may be reserved for extensive AKs not controlled with cryotherapy or topical 5‑FU.
• No formal step therapy mandated by this policy; evidence may favor 5‑FU or PDT ahead of less-studied modalities.

PDT (ALA) prior authorization and documentation considerations

Specific clinical/operational considerations for topical ALA PDT (e.g., Ameluz 10% gel) should be documented when used, particularly for large‑area treatments. Documents should support the indication, treatment area, and expected post‑treatment care to help substantiate medical necessity.

• Record treated surface area (noting studies reporting use up to 75–300 cm2).
• Document product used (ALA 10% gel vs ALA 20% solution), light source (blue or red), incubation time, and post‑PDT care instructions.
• Note if treatment is lesion‑directed or field‑directed and rationale (e.g., extensive or refractory AKs, organ transplant recipient).

Denial risk — evidence limitations

Evidence limitations for newer or less‑studied interventions (small trials, first‑in‑human studies, or techniques listed as investigational) may lead to claim denials or coverage exclusions. Providers should cite RCT data or guideline support when available.

• Interventions considered investigational by this policy (may trigger denial): thermal photodynamic therapy, repetitive daylight PDT for prevention, microwave therapy (pending larger RCTs), microneedling, topical agents lacking evidence.
• Provide trial identifiers, peer‑reviewed publications, and rationale when requesting coverage for less-established treatments.

Provider responsibility — policy scope and benefit verification

Clinical Policy Bulletins (CPBs) summarize clinical evidence and coverage positions but do not guarantee payment. Providers remain responsible for verifying member benefits, obtaining any required authorizations, and for treatment decisions.

• CPB content is informational and may be updated; always confirm plan-specific coverage and benefit design.
• Obtain prior authorization if required by the member’s plan and document medical necessity in the record.

Specimen submission when carcinoma suspected

When curettage or excision is performed because invasive squamous cell carcinoma (SCC) is suspected, submission of the specimen for histologic analysis is required and should be documented in the medical record.

• Include pathology report or specimen submission documentation in the patient record when SCC is suspected.
• Curettage/excision for suspected carcinoma is considered medically necessary when histologic analysis is indicated.

No explicit documentation/authorization workflow provided

This excerpt does not list explicit documentation or authorization steps beyond standard medical-record documentation and plan-level prior authorization processes. Clinical justification (lesion characteristics, prior therapies tried, and rationale for modality choice) should be included in requests.

• Document prior treatments and responses (e.g., prior cryotherapy, topical 5‑FU or imiquimod) when seeking coverage for alternative modalities.
• State lesion location, size, number, and whether lesion‑directed or field‑directed therapy is required.

Evidence documentation expectations

Summarize and cite relevant evidence when requesting coverage for treatments. The policy references systematic reviews, network meta-analyses, RCTs, and guideline statements as the basis for recommendations and coverage positions.

• Preferred supporting evidence: RCTs, Cochrane or systematic reviews, guideline recommendations (e.g., British Association of Dermatologists, European Dermatology Forum).
• Include lesion‑level and participant‑level outcome data when available (clearance rates, adverse events).

Document treatment area and post‑PDT care

For large-area PDT treatments, document the exact area treated and the post‑PDT care regimen provided and followed by the patient (e.g., zinc oxide, healing creams, sun protection) because adverse effects and mitigation strategies are relevant to medical necessity and safety.

• If treating >20 cm2 (FDA‑largest approved field for some products), include rationale for larger field and documentation of patient counseling and post‑treatment instructions.
• Note any deviations from manufacturer‑recommended incubation or illumination protocols with clinical justification.

Treatment sequencing and guideline‑style recommendations

Treatment sequencing considerations: cryosurgery, topical therapies (5‑FU, imiquimod, diclofenac, ingenol mebutate), and curettage/excision (when SCC suspected) are first‑line options. PDT is often considered for extensive or refractory AKs; no formal step‑therapy requirements are specified in this policy excerpt.

• Consider 5‑FU or imiquimod for field therapy, especially in organ transplant recipients where RCT data support topical agents.
• PDT may be preferred for superficial, confluent, or extensive lesions not controlled by standard therapies.

Policy history and versioning

Policy history and review dates are provided in the policy header; ensure requests reflect the current policy effective date and most recent review.

• Policy Effective Date: 11/09/2001; Last Review: 08/10/2023; Next Review: 06/13/2024.
• Use current policy version when preparing prior authorization or coverage justification.